| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69b74d6645b90e2b6717270061ee57d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_785ac2b35073f5a6d251678e6fb31b6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33adfa978ae65926f40b3067de900ad2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3525 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7125 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate |
2013-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_783795a2de5972eedff32bf3bfc585db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_924ae3a16ad41f18bb0cdd5ac17aa688
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8c863222bafaf057729a89184e9794b |
| publicationDate |
2015-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2877579-A1 |
| titleOfInvention |
Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen |
| abstract |
Disclosed herein are antisense compounds and methods for modulating AGT and modulating a RAS pathway related disease, disorder or condition in an individual in need thereof. RAS related diseases in an individual such as hypertension or organ damage can be treated, ameliorated or prevented with the administration of antisense compounds targeted to AGT. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4035659-A1 |
| priorityDate |
2012-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |